Exploration of lung mycobiome in the patients with non-small-cell lung cancer

被引:13
|
作者
Zhao, Yiming [1 ,2 ]
Yi, Junqi [1 ,3 ]
Xiang, Juanjuan [3 ,4 ,5 ]
Jia, Wei [6 ]
Chen, Anqi [1 ]
Chen, Liyu [2 ]
Zheng, Leliang [4 ,5 ]
Zhou, Wen [4 ,5 ]
Wu, Minghua [4 ,5 ]
Yu, Zheng [2 ]
Tang, Jingqun [1 ,3 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Microbiol, Changsha, Hunan, Peoples R China
[3] Hunan Key Lab Early Diag & Precise Treatment Lung, Changsha, Hunan, Peoples R China
[4] Cent South Univ, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Chinese Minist Educ,Key Lab Carcinogenesis & Canc, Changsha, Hunan, Peoples R China
[6] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tong, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-small-cell lung cancer; Mycobiome; Alternaria arborescens; ACETALDEHYDE PRODUCTION; MICROBIOME; COMMUNITY; INFLAMMATION; INFECTIONS; IMMUNITY;
D O I
10.1186/s12866-023-02790-4
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
As the Human Microbiome Project (HMP) progresses, the relationship between microbes and human health has been receiving increasing attention. A growing number of reports support the correlation between cancer and microbes. However, most studies have focused on bacteria, rather than fungal communities. In this study, we studied the alteration in lung mycobiome in patients with non-small-cell lung cancer (NSCLC) using metagenomic sequencing and qPCR. The higher fungal diversity and more complex network were observed in the patients with NSCLC. In addition, Alternaria arborescens was found as the most relevant fungus to NSCLC, and the enrichment of it in cancerous tissue was also detected. This study proposes that the changes in fungal communities may be closely related to lung cancer, and provides insights into further exploration the relationship between lung cancer and fungi.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Bevacizumab in non-small-cell lung cancer: a review
    Planchard, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (08) : 1163 - 1179
  • [22] Selumetinib in the treatment of non-small-cell lung cancer
    Bernabe, Reyes
    Patrao, Ana
    Carter, Louise
    Blackhall, Fiona
    Dean, Emma
    FUTURE ONCOLOGY, 2016, 12 (22) : 2545 - 2560
  • [23] Surgical treatment of non-small-cell lung cancer
    Schuhan, C.
    Dienemann, H.
    ONKOLOGE, 2011, 17 (08): : 684 - +
  • [24] β-blockers and metastasis in non-small-cell lung cancer
    Wang, Hongmei
    Gomez, Daniel R.
    Liao, Zhongxing
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (06) : 641 - 643
  • [25] Gefitinib for non-small-cell lung cancer treatment
    D'Incecco, Armida
    Cappuzzo, Federico
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) : 987 - 996
  • [26] Antiangiogenic therapies in non-small-cell lung cancer
    Alshangiti, A.
    Chandhoke, G.
    Ellis, P. M.
    CURRENT ONCOLOGY, 2018, 25 : S45 - S58
  • [27] Gefitinib for the treatment of non-small-cell lung cancer
    Hida, Toyoaki
    Ogawa, Shizu
    Park, Jang Chul
    Park, Ji Young
    Shimizu, Junichi
    Horio, Yoshitsugu
    Yoshida, Kimihide
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (01) : 17 - 35
  • [28] A Review of Immunotherapy in Non-Small-Cell Lung Cancer
    Capella, Mariana Pilon
    Pang, Steph A.
    Magalhaes, Marcos A.
    Esfahani, Khashayar
    CURRENT ONCOLOGY, 2024, 31 (06) : 3495 - 3512
  • [29] Rare mutations in non-small-cell lung cancer
    D'Arcangelo, Manolo
    D'Incecco, Armida
    Cappuzzo, Federico
    FUTURE ONCOLOGY, 2013, 9 (05) : 699 - 711
  • [30] Trastuzumab for the treatment of non-small-cell lung cancer
    Ferrone, M
    Motl, SE
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (12) : 1904 - 1908